A phase 1 trial of 4-(N-(S-penicillaminylacetyl)amino)-phenylarsonous acid (PENAO) in patients with advanced solid tumours
- 26 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Chemotherapy and Pharmacology
- Vol. 87 (5), 613-620
- https://doi.org/10.1007/s00280-020-04225-7
Abstract
Purpose This phase I study was conducted to evaluate the safety and Maximum Tolerated Dose of PENAO (4-(N-(S-penicillaminylacetyl)amino)-phenylarsonous acid), a second-generation organic arsenical with anti-mitochondrial activity, when given as a continuous intravenous infusion (CIVI), in patients with advanced solid tumours. Methods Eligibility criteria for this trial included age ≥ 18 years, advanced solid tumour, ECOG Performance Status ≤ 1 and adequate organ function. PENAO was administered by CIVI, with dose levels initially increased by infusion duration in a 21-day cycle at a fixed daily dose and then increased daily dose. Standard dose-limiting toxicity (DLT) definitions were used in a “3 + 3” design. Patients had regular monitoring of toxicity and efficacy. Pharmacokinetic assays of serum and urine As were performed. Results Twenty-six patients were treated across 8 dose levels. The only dose-limiting toxicity (DLT) observed was fatigue, that occurred in one patient treated at the highest dose level of 9 mg/m2/day. No significant organ toxicity or objective responses were observed, although there were two patients with stable disease lasting up to 7 months. Pharmacokinetic analysis unexpectedly indicated a half-life of 9–19 days, invalidating the CIVI dosing resulting in discontinuation of the study before the RP2D was defined. Conclusions PENAO was administered by CIVI at dose levels up to 9 mg/m2/day with only one DLT noted. Pharmacokinetic studies invalidated the rationale for continuous dosing and led to discontinuation of the trial without defining a RP2D. Future clinical development of PENAO will use intermittent dosing schedule, alone and in combination with rapamycin.Keywords
Funding Information
- National Health and Medical Research Council (1002645, 1110219)
- Cancer Council NSW (PG 11-03)
- Australian Cancer Research Foundation
- UNSW Foundation
This publication has 24 references indexed in Scilit:
- A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumoursCancer Chemotherapy and Pharmacology, 2013
- The pivotal roles of mitochondria in cancer: Warburg and beyond and encouraging prospects for effective therapiesBiochimica et Biophysica Acta (BBA) - Bioenergetics, 2010
- Optimization of the Antitumor Efficacy of a Synthetic Mitochondrial Toxin by Increasing the Residence Time in the CytosolJournal of Medicinal Chemistry, 2009
- A Phase I Clinical Trial of Darinaparsin in Patients with Refractory Solid TumorsClinical Cancer Research, 2009
- What is the mitochondrial permeability transition pore?Journal of Molecular and Cellular Cardiology, 2009
- Clinical outcomes and rates of molecular remission with all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) combination therapy in newly diagnosed acute promyelocytic leukemia (APL)Journal of Clinical Oncology, 2006
- A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patientsLeukemia, 2004
- Clinical study of an organic arsenical, melarsoprol, in patients with advanced leukemiaCancer Chemotherapy and Pharmacology, 1999
- Differences in expression and intracellular distribution of hexokinase isoenzymes in rat liver cells of different transformation stagesBiochimica et Biophysica Acta (BBA) - Gene Structure and Expression, 1994
- The Treatment of Human African TrypanosomiasisPublished by Elsevier BV ,1994